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Abstract
Background: Bile duct reconstruction (BDR) is used to manage benign and malignant neoplasms,
congenital anomalies, bile duct injuries and other non-malignant diseases. BDR outcomes overall, by
year, and by indication were compared.
Methods: Retrospective analysis of Nationwide Inpatient Sample discharges (2004–2011) including
ICD-9 codes for BDR. All statistical testing was performed using survey weighting. Univariate analysis
of admission characteristics by chi square testing. Multivariate modelling for inpatient complications
and inpatient death by logistic regression.
Results: Identified 67 160 weighted patient admissions: 2.5% congenital anomaly, 37.4% malignant
neoplasm, 2.3% benign neoplasm, 9.9% biliary injury, 47.9% other non-malignant disease. Most BDRs
were performed in teaching hospitals (69.6%) but only 25% at centres with a BDR volume more than
35/year. 32.3% involved ≥ 1 complication, and 84.7% were discharges home. There was a 4.2% inpa-
tient death rate. The complication rate increased but the inpatient death rate decreased over time. The
rates of acute renal failure increased. Significant multivariate predictors of inpatient death include indi-
cation of biliary injury or malignancy, and predictors of any complication include public insurance and
non-elective admission.
Conclusion: This is the first national description of BDRs using a large database. In this diverse
sampling, both procedure indication and patient characteristics influence morbidity and mortality.
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Introduction
The term bile duct reconstruction (BDR) encompasses a vari-
ety of surgical procedures with one overarching purpose: to
restore the natural flow of bile from the liver to the intestines.
The indications for BDR are numerous, ranging from biliary
trauma to malignancy to non-malignant diseases to congenital
problems. However, the national rate of BDRs in the United
States is unknown.
The literature on outcomes for BDR is sparse and mostly
limited to small, single-centre studies that evaluate particular
types of reconstructions in specific populations.1–4 A great deal
of the literature using nationwide data has focused on biliary
tract malignancies5,6 and the prevention7 or changing manage-
ment of bile duct injuries.8,9
As the first investigation at the national scale of admissions
for BDRs of all types, we aim to characterize the population
receiving these procedures, identify trends in BDR and distin-
guish factors associated with worse inpatient outcomes.
Patients and methods
Patient population
A retrospective, population-based analysis was performed
using discharge records from the Nationwide Inpatient
Sample (NIS) for the years 2004–2011. As the largest
national hospital inpatient administrative database in the
US, the NIS provides a 20% sample of short-term, non-fed-
eral hospitals, amounting to 40 million weighted admissions
annually.10
This study was presented at the Annual Meeting of the AHPBA, 11-15
March 2015, Miami, Florida.
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Inclusion criteria were patient age ≥ 18 years and an ICD-9
procedure code suggestive of BDR: 51.36, 51.37, 51.39 (chole-
dochoenterostomy), 51.69, 51.63 (excision of bile duct), 51.72,
51.79 (choledochoplasty), 51.93 (closure of biliary fistula) and
51.94 (revision of biliary anastomosis). Exclusion criteria
included any diagnosis code of liver transplant or associated
transplant complications. Admissions with missing data for
age, gender, inpatient death, length of stay (LOS), elective
status and hospital information were also excluded.
Patient and hospital characteristics
Patient characteristics of interest were gender, age, race, quar-
tile for median household income based on the patient’s ZIP
code, insurance status, concomitant diagnoses and the Elixha-
user comorbidity score, calculated using the Healthcare Cost
and Utilization Project Comorbidity Software, Version 3.7.11
Hospital characteristics included teaching status and annual
BDR volume. High BDR volume hospitals were those in the
top tertile of facilities included, defined as those performing
> 25 BDRs per year.
Admission characteristics
Admissions were divided into five hierarchical groups based
on the indication for BDR: congenital anomaly (including
choledochal cyst), malignant neoplasm, benign neoplasm,
bile duct injury or trauma and other non-malignant disease.
A malignant neoplasm refers to any primary or secondary
malignant neoplasm or neoplasm of uncertain behaviour,
including carcinoma in situ and malignancies of the liver, bili-
ary system, stomach, pancreas, small intestine, large intestine,
spleen, retroperitoneum and abdominal lymph nodes. The
‘other non-malignant disease category’ included strictures,
non-malignant obstructions and non-congenital cysts, as well
as any remaining non-malignant biliary processes. Dual diag-
noses were not permitted, and admission indications were
categorized based on the aforementioned hierarchy. Please
refer to Appendix A1 for a list of ICD-9 codes by procedure
and diagnosis.
Admissions were further characterized by year range (2004–
2006, 2007–2009 and 2010–2011) as well as urgency of admis-
sion. Imaging type, including intra-operative cholangiogram
(IOC) or biliary X-ray, endoscopic retrograde cholangiogram
(ERC) or endoscopic retrograde cholangiopancreatography
(ERCP), diagnostic ultrasound, CT scan, MRI or magnetic
resonance cholangiopancreatography (MRCP), performed dur-
ing a BDR-related admission was identified by ICD-9 code.
Outcomes
Outcomes of interest included inpatient complications (listed
in Appendix A1) and mortality, LOS, disposition status and
cost, which was determined using supplemental NIS HCUP
Cost-to-Charge Ratio files.12
Statistical analysis
All statistical analysis was performed using the weighted survey
methods in SAS (version 9.3/9.4; SAS Institute, Cary, NC,
USA), and all amounts reported are weighted values. P-values
of < 0.05 were considered significant. Continuous variables
were divided into categories based on clinical significance. Uni-
variate analysis was performed using chi-square tests. The
Cochran–Armitage trend test was used to assess for trends over
time across year groups.
A subset analysis comparing outcomes in BDRs performed
with hepatectomies (ICD-9 procedure codes 50.22 or 50.3) and
without hepatectomies for malignant neoplasm was performed.
Logistic regression models were created for inpatient death
and any complication. Covariates were included in the models
based on an univariate screen, with confounding prioritized
over collinearity in the process of model building. Considered
for insertion into the models were: indication, BDR procedure,
gender, race, income quartile, insurance type, age category,
Elixhauser score, elective status, hospital teaching status, hospi-
tal volume cluster and year category. Additionally, post-opera-
tive infection, cholangitis, acute pancreatitis, acute renal
failure, acute liver failure, operative bleeding, deep vein throm-
bosis (DVT)/pulmonary embolism (PE), acute myocardial
infarction (MI) and gastrointestinal (GI) bleed were considered
for insertion into the inpatient death model. Indication was
collapsed into three categories (malignant, non-malignant and
biliary injury/trauma) for the inpatient death model in order
to avoid small cell sizes and model instability.
Results
Patient and hospital characteristics
Sixty-seven thousand one hundred and sixty weighted admis-
sions in which a BDR was performed were identified over an
8-year period. One thousand six hundred and seventy-five
BDRs (2.5%) were performed for congenital anomalies, 25 150
(37.4%) for malignancy, 1528 (2.3%) for benign neoplasms,
6653 (9.9%) for biliary injury/trauma and 32 155 (47.9%) for
other non-malignant disease. The majority involved women
(37 119, 55.3%), white patients (39 190, 58.4%) and patients
with government insurance (36 540, 54.4%). The distribution
for age was left-skewed, with 45.3% of patients (30 403) age
65 years or older. A plurality of BDR-related admissions
(25 075, 37.3%) involved patients with an Elixhauser score of
3 or greater. 69.6% (46 743) were admissions to a teaching
hospital. Please see Table 1 for a comparison of characteristics
by indication. The median yearly volume of BDRs per hospital
was 10, with an interquartile range of 4–35.
In the cohort of BDRs conducted for malignancy, pancreatic
malignancy was the most common indication for BDR
(13 590, 53.9%), followed by liver maligancy at 25.3% (6391),
extra-hepatic biliary malignancy at 14.1% (3558), intra-hepatic
biliary malignancy at 7.4% (1875), gallbladder malignancy at
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Table 1 Patient and hospital characteristics by indication for bile duct reconstruction
Congenital
anomaly
1675
Malignant
neoplasm
25 150
Benign
neoplasm
1528
Biliary
injury or
trauma
6653
Other
non-malignant
disease 32 155
Total
67 160
P-value
n % n % n % n % n % %
Gender
Male 441 26.3 13 385 53.2 619 40.5 2382 35.8 13 214 41.1 44.7 <0.0001
Female 1233 73.7 11 765 46.8 909 59.5 4271 64.2 18 941 58.9 55.3
Age
< 40 years 592 35.4 486 1.9 128 8.4 1718 25.8 4907 15.3 11.7 <0.0001
40–64 years 727 43.4 10 717 42.6 714 46.7 2680 40.3 14 088 43.8 43.1
≥ 65 years 355 21.2 13 946 55.5 686 44.9 2255 33.9 13 161 40.9 45.3
Race
White 930 55.5 15 674 62.3 870 56.9 3627 54.5 18 088 56.3 58.4 <0.0001
Black 102 6.1 1705 6.8 165 10.8 515 7.7 2235 6.9 7.0
Other/Unknown 642 38.4 7770 30.9 493 32.3 2510 37.7 11 832 36.8 34.6
Income Quartile by ZIP Code
Less than 25th percentile 371 22.1 6149 24.4 358 23.4 1891 28.4 8490 26.4 25.7 0.0002
26–50th percentile 452 27.0 6263 24.9 331 21.7 1736 26.1 8682 27.0 26.0
51–75th percentile 433 25.9 5958 23.7 421 27.6 1644 24.7 7383 23.0 23.6
76–100th percentile 379 22.6 6126 24.4 398 26.0 1250 18.8 6786 21.1 22.2
Insurance
Government 587 35.0 14 752 58.7 821 53.7 3207 48.2 17 174 53.4 54.4 <0.0001
Private 836 49.9 9060 36.0 648 42.4 2786 41.9 11 869 36.9 37.5
Other/unknown 252 15.2 1337 5.3 59 3.9 660 9.9 3112 9.7 8.1
Elixhauser score
0 542 32.4 1672 6.6 357 23.4 1873 28.2 6639 20.6 16.5 <0.0001
1 484 28.9 5143 20.4 413 27.1 1628 24.5 7788 24.2 23.0
2 339 20.2 6366 25.3 344 22.5 1364 20.5 7132 22.2 23.1
≥3 310 18.5 11 969 47.6 413 27.0 1788 26.9 10 596 33.0 37.3
Elective Status
Elective 1019 60.8 17 069 67.9 1200 78.6 2519 37.9 14 813 46.1 54.5 <0.0001
Non-elective 655 39.1 8081 32.1 328 21.4 4135 62.1 17 342 53.9 45.5
Hospital type
Teaching 1107 66.1 20 037 79.7 1249 81.7 4334 65.1 20 016 62.2 69.6 <0.0001
Non-teaching 567 33.9 5113 20.3 279 18.3 2319 34.9 12 139 37.8 30.4
Hospital BDR volume
Low volume (≤5) 708 42.3 5764 22.9 410 26.9 2940 44.2 13 866 43.1 35.3 <0.0001
Medium volume (6–25) 479 28.6 9048 36.0 442 28.9 1963 29.5 10 373 32.3 33.2
High volume (>25) 488 29.1 10 337 41.1 675 44.2 1751 26.3 7916 24.6 31.5
Year
2004–2006 544 32.5 9065 36.0 510 33.4 2439 36.7 12 814 39.9 37.8 0.0155
2007–2009 679 40.6 9530 37.9 583 38.1 2404 36.1 11 726 36.5 37.1
2010–2011 451 26.9 6554 26.1 435 28.5 1809 27.2 7615 23.7 25.1
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6.1% (1545) and malignancy in a non-specific liver, gallbladder
or biliary location at 3.1% (789).
As seen in Table 2, 9.0% of BDR-related admissions (6015)
involved a concomitant diagnosis of cholangitis, 6.9% (4634)
acute pancreatitis and 2.1% (1404) a bile duct fistula. The
highest rate of all concomitant diagnoses was seen in the other
non-malignant disease group with 12.4% of admissions (3988)
with cholangitis, 9.2% (2952) with acute pancreatitis and 3.7%
(1203) with a bile duct fistula. Within the other non-malignant
disease group, 61.6% of admissions (19 811) had a diagnosis
of cholelithiasis, cholecystitis or cholangitis and 2.2% had bili-
ary stent failure (705).
The rate of concomitant hepatectomy also varied by indica-
tion, with hepatectomies performed with 15.6% (3919) of
BDRs for a malignant neoplasm, 7.8% (119) for a benign neo-
plasm, 5.9% (99) for a congenital anomaly and less than 2%
for other non-malignant disease and biliary injury or trauma
(626 and 118, respectively).
Admission characteristics
Nearly one-third of BDR-related admissions (22 122, 32.9%)
involved imaging. The most common type of imaging per-
formed was an IOC, or biliary X-ray (16 048, 23.9% of admis-
sions) and the least common was MRI or MRCP (394, 0.6%).
As shown in Table 2, the rate of any imaging performed dur-
ing the same admission as a BDR decreased over time
(P < 0.0001); the only type of imaging to increase in use was
diagnostic ultrasound (P < 0.0001).
The mean number of BDRs performed per year was 8395
with the greatest number performed in 2008 (9430, 14.0%).
54.5% of admissions for BDR (36 620) were elective. The
greatest rates of BDRs performed electively were for malignant
Table 2 Time trends in admission characteristics and outcomes for bile duct reconstruction
2004–2006 2007–2009 2010–2011 All BDR Admissions P-value
25 373 24 922 16 865 67 160
n % n % n % n %
Any imaging 9099 35.9 8103 32.5 4920 29.2 22 122 32.9 <0.0001
IOC or Biliary X-ray 6744 26.6 5825 23.4 3480 20.6 16 048 23.9 <0.0001
ERC or ERCP 2772 10.9 1889 7.6 1048 6.2 5709 8.5 <0.0001
Diagnostic ultrasound 448 1.8 836 3.4 778 4.6 2063 3.1 <0.0001
CT scan 414 1.6 535 2.1 299 1.8 1247 1.9 0.1173
MRI/MRCP 135 0.5 177 0.7 82 0.5 394 0.6 0.8340
Any complication 7427 29.3 8473 34.0 5800 34.4 21 700 32.3 <0.0001
Post-operative infection 2919 11.5 3585 14.4 2482 14.7 8986 13.4 <0.0001
Acute renal failure 1447 5.7 2375 9.5 2043 12.1 5865 8.7 <0.0001
Operative bleeding 934 3.7 1372 5.5 824 4.9 3131 4.7 <0.0001
GI bleed 436 1.7 648 2.6 318 1.9 1402 2.1 0.0381
Acute liver failure 202 0.8 445 1.8 335 2.0 982 1.5 <0.0001
DVT/PE 265 1.0 352 1.4 272 1.6 890 1.3 <0.0001
Acute MI 243 1.0 294 1.2 105 0.6 642 1.0 0.0042
Concomitant diagnoses
Cholangitis 2329 9.2 2258 9.1 1429 8.5 6015 9.0 0.0170
Acute pancreatitis 1623 6.4 1900 7.6 1111 6.6 4634 6.9 0.1470
Bile duct fistula 556 2.2 505 2.0 343 2.0 1404 2.1 0.2321
Concomitant procedure
Hepatectomy 1348 5.3 1850 7.4 1682 10.0 4880 7.3 <0.0001
Elective 13 174 51.9 13 371 53.7 10 074 59.7 36 620 54.5 <0.0001
Inpatient death 1102 4.3 1051 4.2 648 3.8 2802 4.2 0.0148
Length of stay > 14 days 6858 27.0 6588 26.4 4521 26.8 17 966 26.8 0.4922
Cost > $40,000 4481 18.9 5925 25.3 4460 28.8 14 865 23.7 <0.0001
BDR, bile duct reconstruction; DVT/PE, deep vein thrombosis/pulmonary embolism; ERC, endoscopic retrograde cholangiogram; ERCP, endo-
scopic retrograde cholangiopancreatography; GI, gastrointestinal; IOC, intra-operative cholangiogram; MI, myocardial infarction; MRCP, magnetic
resonance cholangiopancreatography; MRI, magnetic resonance imaging.
HPB 2015, 17, 753–762 ª 2015 International Hepato-Pancreato-Biliary Association
756 HPB
and benign neoplasms (17 069, 67.9 and 1200, 78.6%, respec-
tively). The rate of elective admissions increased over time
(P < 0.0001).
Outcomes
Nearly one-third (21 700, 32.3%) of admissions involved at
least one complication. The most common coded complication
was a post-operative infection, occurring in 13.4% (8986) of
all admissions. DVT/PE and acute MI were the least common
complications, only occurring in 1.3% (890) and 1.0% of
admissions (642), respectively. Operative bleeding occurred in
4.7% (3 131) of BDR-related admissions. The rate of any doc-
umented complication increased over time (P < 0.0001), with
a notable increase in rates of post-operative acute renal failure
(P < 0.0001), as seen in Table 2.
Within the malignant neoplasm cohort, the mortality rate
for BDR when no concomitant hepatectomy was performed
was 5.1% (1085/21 279) versus 10.5% (412/3942) when per-
formed with a hepatectomy (P < 0.0001). Similarly, the com-
plication rate with no concomitant hepatectomy was 33.1%
(7042/21 279) versus 41.3% (1628/3942) with a hepatectomy
(P = 0.0002). As shown in Table 2, there has been an increase
in concomitant hepatectomies over time (P < 0.0001).
The median LOS was 9 days (IQR 6, 15), with the majority
of admissions (31 076, 46.3%) lasting between 1 and 2 weeks.
The shortest LOSs were for BDRs performed for congenital
anomalies, with 46.9% (786) of those admissions lasting less
than a week. In contrast, the longest LOSs were for those
admissions during which a BDR was performed for malignant
disease, with almost one-third (8233, 32.7%) lasting longer
than 2 weeks. The rate of admissions that lasted longer than
2 weeks did not change significantly over time (0.4922).
4.2% (2 802) of BDR-related admissions resulted in inpa-
tient death. 5.9% (1 492) of admissions for BDR performed
for malignancy resulted in inpatient death, in contrast to 4.1%
(275) for biliary injury or trauma, and 3.0% (980) for other
non-malignant disease. The rates of inpatient death for con-
genital anomalies and benign neoplasms were too low to
report. The majority of inpatient deaths (1577, 56.3%)
occurred in admissions that lasted over 2 weeks. The rate of
inpatient death decreased over time (P = 0.0148).
For any admission resulting in discharge alive from the hos-
pital, 84.7% (54 531) were discharges home (versus rehabilita-
tion centre or skilled nursing facility). The lowest rates of
discharge home were for biliary injury or trauma (5294,
83.0%), a malignant neoplasm (20 027, 84.7%) and other non-
malignant disease (26 393, 84.7%).
Among the 62 633 admissions with complete cost data,
median cost was $22 230 (IQR $14 399, $38 358.) Of these
admissions, 23.7% (14 865) cost more than $40 000, with the
rate of these costly admissions increasing over time (P <
0.0001). 38.8% of BDR admissions for the congenital anomaly
(650) cost less than $15 000. Please refer to Table 3 for out-
comes by indication.
Multivariate analysis
Significant predictors for inpatient death, highlighted in
Table 4, include biliary injury or trauma (versus non-malig-
nant disease), malignant disease (versus non-malignant disease),
revision of biliary anastomosis (versus choledochoenterostomy),
Table 3 Outcomes by indication for bile duct reconstruction
Congenital
anomaly
Malignant
neoplasm
Benign
neoplasm
Biliary
injury or
trauma
Other
Non-malignant
disease
All BDR
admissions
P-value
1675 25 150 1 528 6 653 32 155 67 160
N % n % n % n % n % n %
LOS
<7 days 786 46.9 4418 17.6 338 22.1 2130 32.0 10 447 32.5 18 119 27.0 <0.0001
7–14 days 626 37.4 12 499 49.7 770 50.4 3007 45.2 14 174 44.1 31 076 46.3
>14 days 263 15.7 8233 32.7 421 27.5 1516 22.8 7534 23.4 17 966 26.7
Median LOS (IQR) 7 (5, 10) 10 (7, 17) 10 (7, 16) 8 (6, 14) 8 (6, 14) 9 (6, 15) <0.0001
Cost per admission
<$15 000 650 38.8 3758 14.9 245 16.0 1927 29.0 10 416 32.4 16 996 25.3 <0.0001
$15 000–40 000 709 42.3 12 945 51.5 818 53.5 3012 45.3 13 289 41.3 30 772 45.8
>$40 000 211 12.6 6714 26.7 349 22.8 1282 19.3 6310 19.6 14 865 22.1
Median cost (IQR) 16 546
(11 247,
26 924)
26 825
(17 873,
43 524)
25 529
(17 313,
39 646)
20 844
(13 235,
34 744)
19 280
(12 441,
34 468)
22 230
(14 399,
38 358)
<0.0001
Discharged Home 1536 93.0 20 027 84.7 1 282 85.8 5 294 83.0 26 393 84.7 54 531 84.7 0.0012
BDR, bile duct reconstruction; IQR, interquartile range; LOS, length of stay.
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Table 4 Model of inpatient death for bile duct reconstruction
Unadjusted OR [95% CI] Adjusted OR [95% CI]
Indication
Non-malignant disease Ref
Biliary injury or trauma 1.429 1.068 1.914 1.757 1.240 2.489
Malignant disease 2.091 1.719 2.543 2.147 1.703 2.706
Type of Bile duct reconstruction
Choledochoenterostomy Ref
Choledochoplasty 0.946 0.727 1.232 0.935 0.667 1.311
Closure of biliary fistula 0.945 0.663 1.347 1.022 0.666 1.570
Excision of bile duct 1.002 0.662 1.518 0.804 0.490 1.319
Revision of biliary anastomosis 3.302 2.183 4.996 3.053 1.890 4.934
Gender
Male 1.293 1.093 1.529 0.908 0.745 1.106
Female Ref
Payer Type
Private Insurance Ref
Public Insurance 3.061 2.474 3.786 1.641 1.224 2.200
Other Insurance 1.190 0.767 1.846 1.560 0.988 2.463
Age category
Younger than 40 years Ref
Age 40–64 years 3.558 1.741 7.272 2.827 1.381 5.786
Age > 64 years 10.463 5.295 20.673 6.324 3.024 13.224
Elixhauser Score
0 Ref
1 1.616 1.063 2.457 0.883 0.576 1.356
2 2.079 1.402 3.085 0.837 0.556 1.258
≥3 3.644 2.512 5.287 0.931 0.623 1.390
Elective status
Elective Ref
Non-elective 1.498 1.259 1.781 1.125 0.908 1.394
Complications
Post-operative infection 3.770 3.068 4.633 2.001 1.584 2.528
Acute renal failure 13.595 11.400 16.211 7.858 6.289 9.819
Operative bleeding 4.185 3.275 5.347 2.481 1.883 3.270
GI bleed 6.286 4.526 8.731 3.154 2.123 4.684
DVT/PE 4.778 3.118 7.321 2.270 1.285 4.013
Acute MI 8.257 5.650 12.066 3.065 1.783 5.268
Acute liver failure 15.530 11.491 20.989 6.510 4.413 9.604
Concomitant diagnoses
Cholangitis 1.346 1.043 1.736 1.144 0.837 1.564
Acute pancreatitis 1.484 1.128 1.954 1.189 0.846 1.672
Hospital teaching status
Teaching Ref
Non-teaching 1.201 0.988 1.460 1.273 1.012 1.601
CI, confidence interval; DVT/PE, deep vein thrombosis/pulmonary embolism; GI, gastrointestinal; MI, myocardial infarction; OR, odds ratio.
Other covariates in the model: Elixhauser score, gender, elective status, cholangitis, acute pancreatitis. Bold values represent statistically signifi-
cant odds ratio.
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public insurance (versus private insurance), age 40–64 years
(versus younger than 40 years), age < 64 years (versus younger
than 40 years), post-operative infection, acute renal failure,
operative bleeding, GI bleed, DVT/PE, acute MI and acute liver
failure.
Included in the final model for any complication were: indi-
cation, BDR procedure, gender, insurance type, age category,
Elixhauser score, elective status, year category and race. Signifi-
cant predictors are depicted in Fig. 1.
Discussion
Even with the rising popularity of minimally invasive and
endoscopic techniques,13,14 operative BDR remains a common
procedure in the United States. Other non-malignant disease
was the most common indication for a BDR, followed by
malignant neoplasm, biliary injury, congenital anomaly and
benign neoplasm. This study highlights that the burden of gall-
stone disease in this country extends beyond laparoscopic cho-
lecystectomy and biliary stent placement and into more
complex surgeries such as BDR. Although 32.3% of BDR-
related admissions (21 700) involved at least one complication,
only 4.2% of admissions (2802) resulted in inpatient death. In
the malignant neoplasm group, the mortality rate more than
doubled and the complication rate also rose when a concomi-
tant hepatectomy was performed.
Our results are generally concordant with an assortment
of previously published studies that have focused on specific
indications or procedures in various settings,15–17 although
different classification schemes make direct comparison diffi-
cult. Small international studies of BDRs for benign biliary
lesions (defined broadly) document post-operative complica-
tion rates of 13–49% and peri-operative mortality rates of
0–5%.18–22 Peri-operative mortality in a study of a choledo-
choduodenostomy for benign versus malignant disease in
Israel from 1988 showed a peri-operative mortality rate of
about 3.1% versus 8.6%, respectively.20 The previously
reported peri-operative mortality rate is 1.7–4.5% and the
complication rate 42–43% for patients undergoing biliary
reconstruction for biliary injury after a laparoscopic cholecys-
tectomy.9,23
In addition to being the first comprehensive study of BDRs
in this country, our study sheds light on several aspects of
BDRs that have been overlooked in the literature.
Although the volumes–outcome relationship has been well-
established for complex surgical procedures including liver
transplantation,24,25 a large number of BDRs, namely for con-
genital anomalies, non-malignant disease and biliary trauma,
are still being performed at low-volume centres. Overall, 50%
of BDRs were performed in centres with a yearly BDR volume
of < 10 and 25% in centres with a yearly volume of < 4. It is
important to note that this volume data is only based on the
20% of hospitals sampled by the NIS.
We have found that several indications, types of procedures
and patient characteristics influenced the odds of any inpatient
complication and inpatient death. Particularly, public insur-
ance (versus private insurance) was both a predictor of inpa-
tient death and complications. Although insurance has been
shown to affect outcomes for various conditions,26,27 this is the
first evidence of the importance of insurance in the field of
biliary surgery.
In addition to providing complication and death rates for
BDR, we also provide information on discharge location, an
important consideration for patients. For all patients dis-
charged alive from the hospital, the rate of discharge home (as
opposed to a rehabilitation facility), was quite high at 84.7%
Figure 1 Adjusted significant predictors of any inpatient complication after bile duct reconstruction. Adjusted odds ratios with 95%
confidence intervals. LCL, lower confidence limit; OR, odds ratio; UCL, upper confidence limit. Other covariates in model: race
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(54 531) for this adult population, over one-third of whom
had an Elixhauser score of 3 or greater.
Furthermore, we provide information on trends in imaging,
cost per admission, LOS, concomitant hepatectomy, complica-
tions and inpatient death rates over an 8-year period. The
decreasing rate of imaging performed during admission for
BDR is an interesting contrast to the increasing rate of costly
admissions and the stable rate of lengthy hospital stays. A clo-
ser look at these costly admissions reveals that the patients are
older and have more comorbidities, with over two-thirds expe-
riencing complications, including an especially high rate of
operative bleeding. It is possible that the increased cost is
related to interventions for these complications. Additionally,
more elective admissions could mean more imaging completed
in the outpatient setting prior to admission for BDR. Accord-
ingly, the decreasing rate of admissions for BDR with a con-
comitant diagnosis of cholangitis could also be as a result of
the more widespread use of stents and endoscopic procedures.
The rate of a hepatectomy performed during the same admis-
sion as a BDR is rising. The increase in the rate of any inpa-
tient complication could be related to more operations
performed on sicker individuals, more technically difficult
BDRs attempted or simply improved accuracy in the coding of
complications. The stark increase in the rate of renal failure is
concerning and should be a focus of special attention moving
forward, especially given the associated high adjusted odds of
inpatient death. In spite of this, there has been a decrease in
the rate of inpatient death. This could be as a result of the
judicious use of pre-operative endoscopic intervention, early
identification and management of complications, or the omis-
sion of death at home or in hospice in this analysis.
There are several limitations to this study. First, the use of
this a large administrative database restricts the available vari-
ables of interest which vary in the level of specificity and are
susceptible to miscoding. The specialty of the operating sur-
geon (general, HPB, surgical oncology, etc.) is not identifiable
from this dataset so any related differences in outcomes cannot
be assessed, although the hospital’s overall level of expertise
with BDRs can be extrapolated from the available volume data.
We were able to provide data on some specific operative com-
plications such as infection and bleeding and several systemic
complications but are unable to quantify other immediate out-
comes such as bile leak owing to the limitations of administra-
tive coding. Data are also restricted to the admission level
without the ability to follow a patient longitudinally. This
study includes initial biliary reconstructions as well as re-oper-
ations and both open and laparoscopic surgeries without a way
to distinguish the two. In addition, neither the specific method
of biliary reconstruction (whether end-to-end, side-to-side, or
duct-to-duct) nor the location of the ductal anastomosis
(duodenum versus jejunum) was available from the available
ICD-9 procedure codes. The order of events during a hospital-
ization is unknown, so it not possible, for example, to ascertain
whether the ‘cholangitis’ coded as a discharge diagnosis was a
reason for admission or a complication of a procedure per-
formed in-house. If more than one BDR was performed on a
given admission, we categorized it in one group based on a
predetermined hierarchy of procedures that prioritized congen-
ital anomalies and malignancies. Cost data were estimated
based on charge and the hospital-payer mix.
Nevertheless, the considerable size of the database over sev-
eral years provides substantial power in the statistical analysis.
We were able to examine both events and indications that are
relatively uncommon, such as congenital anomalies as an indi-
cation for BDR and inpatient death as an outcome.
The population of patients in the US receiving BDRs is pri-
marily older, and a majority are female, white and government
insured. Most reconstructions are performed electively, with
that rate increasing over time. A majority are also performed
at teaching hospitals, but only 25% at centres with an annual
BDR volume of > 35. Almost one-third of admissions involved
an inpatient complication (a rate that has increased over time),
with biliary trauma, choledochoplasty, revision of biliary anas-
tomosis, older age and public insurance among significant pre-
dictors of inpatient complication. Notably, the rate of acute
renal failure after BDR has increased over the last 8 years. Less
than one-third of BDR admissions involved the use of imaging.
The rate of admissions lasting over 2 weeks has remained
stable over time, but the rate of admissions costing over
$40 000 has increased. The inpatient mortality rate has
decreased over time, with biliary trauma, malignant disease,
revision of biliary anastomosis, older age and public insurance
among significant predictors of inpatient mortality.
BDRs are morbid procedures with considerable risk. We have
shown, from a national perspective, that an indication for the
procedure, the procedure itself and patient characteristics signifi-
cantly influence important inpatient outcomes associated with
BDR. We have provided a framework for potential risk stratifica-
tion of patients and data that can improve the counselling of
patients with regards to complications and mortality. Where fea-
sible, we recommend transfer to a centre of excellence for com-
plex BDR. Finally, we advocate for prevention strategies via less
invasive methods to minimize the need for BDR if possible.
We have identified trends, some worrisome and some reas-
suring, in the surgical management of biliary disease. An
understanding of this unique population and the factors influ-
encing morbidity and mortality can lead to more informed
decision making and improved outcomes moving forward.
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Appendix A1 ICD-9 diagnosis and procedure
codes for procedures, indications, imaging,
concomitant diagnoses and complications of
interest
ICD-9 Codes
Procedures
Choledochoenterostomy
51.36, 51.37, 51.39
Excision of bile duct 51.69, 51.63
Choledochoplasty 51.72, 51.79
Closure of biliary
fistula
51.93
Revision of biliary
anastomosis
51.94
Indications
Congenital anomaly
of gallbladder, bile
ducts, liver or
pancreas
751.69, 751.60, 751.61, 751.62, 751.7,
751.8, 751.9
Malignant
neoplasma
Biliary intra-hepatic (155.1)
Biliary extra-hepatic (156.1, 156.2)
Gallbladder (156.0)
Liver (155.0, 155.2, 197.7)
Pancreas (157, 157.x)
Unspecified biliary (156.8, 156.9, 230.8)
Other (151, 151.x, 152, 152.x, 153,
153.x, 156.2, 158, 158.x, 159, 159.x,
197.4, 197.5, 197.6, 197.8, 230.2,
230.3, 230.7, 230.9, 209.0, 209.0x,
209.1, 209.1x, 209.2, 209.2x 196.2,
198.89, 197.8, 235)
Benign neoplasm 209.4, 209.5, 209.6, 211.1, 211.2, 211.3,
211.5, 211.6, 211.7, 211.8, 211.9, 215.5
Bile duct injury or
trauma
576.3, 868.02, 868.12, 998.2
Other
non-malignant
diseaseb
576.2, 576.8, 575.5, 577.2, 577.8,
560.31+ any remaining diagnoses
Imaging
Cholangiogram or
biliary X-ray
87.53, 87.54, 87.59, 87.66
Ultrasound 88.74, 88.76
CT scan of
abdomen
88.01
MRI/MRCP 88.97
ERC/ERCP 51.10, 51.11, 51.19
Concomitant diagnoses
Cholelithiasis/
Cholecystitis
574, 574.x, 574.xx, 575.0, 575.1x, 575.2
Cholangitis 576.1
Acute pancreatitis 577.0
Bile duct fistula 576.4
Complications
Table Continued
ICD-9 Codes
Post-operative
infection
996.64, 999.31, 998.5, 998.51, 998.59,
510, 510.0, 510.9, 513, 513,0, 513.1,
519.2, 590.1, 590.10, 590.11, 590.80,
683, 320, 320.0, 320.1, 320.2, 320.3,
320.7, 320.8, 320.81, 320.82, 320.89,
320.9, 008.4, 008.41, 008.42, 008.43,
008.44, 008.45, 008.46, 008.47, 008.49,
480, 480.0, 480.1, 480.2, 480.3, 480.8,
480.9, 481, 482, 482.0, 482.1, 482.2,
482.3, 482.30, 482.31, 482.32, 482.39,
482.4, 482.40, 482.41, 482.42, 482.49,
482.8, 482.81, 482.82, 482.83, 482.84,
482.89, 482.9, 483, 483.0, 483.1, 483.8,
484, 484.1, 484.3, 484.5, 484.6, 484.7,
484.8, 485, 486, 567.22, 567.3, 567.31,
567.38, 567.39
Acute renal failure 584, 584.5, 584.6, 584.7, 584.8, 584.9
Operative bleeding 998.1, 998.11, 998.12
GI bleed 530.82, 531.0, 531.00, 531.01, 531.1,
531.10, 531.11, 531.2, 531.20, 531.21,
531.3, 531.30, 531.31, 532.0, 532.00,
532.01, 532.1, 532.10, 532.11, 532.2,
532.20, 532.21, 532.3, 532.30, 532.31,
533.0, 533.00, 533.01, 533.11, 533.2,
533.20, 533.21, 533.3, 533.30, 533.31,
534.0, 534.00, 534.01, 534.1, 534.10,
534.11, 534.2, 534.20, 534.21, 534.3,
534.30, 534.31, 535.01, 535.41, 535.51,
535.61, 578, 578.0, 578.1, 578.9
Acute liver failure 570
DVT/PE 415.1, 415.11, 415.12, 415.13, 415.19,
453.4, 453.40, 453.41, 453.42
Acute MI 410, 410.00, 410.01, 410.02, 410.1,
410.11, 410.12, 410.2, 410.21, 410.22,
410.3, 410.30, 410.31, 410.32, 410.4,
410.40, 410.41, 410.42, 410.5, 410.50,
410.51, 410.52, 410.6, 410.60, 410.61,
410.62, 410.7, 410.70, 410.71, 410.72,
410.8, 410.80, 410.81, 410.82, 410.9,
410.91, 410.92
Other complications 507.x, 45.11, 451.11, 451.19, 451.2,
451.81, 453.8, 453.9, 514, 518.4, 518.5,
518.81, 518.82, 530.xx, 54.12, 54.61,
29.51, 31.61, 33.41, 33.43, 42.82,
44.61, 46.71, 46.75, 48.71, 50.61,
51.91, 55.81, 56.82, 57.81, 58.41,
69.41, 569.83, 575.4, 996.69, 996.62,
996.68, 996.63, 996.65, 998.5x, 567.3x,
999.88, 999.39, 995.27, 996.31, 998.13,
997.60, 998.81, 998.89, 569.6x, 536.4x,
998.9, 998.4, 998.0x, 998.7, 998.1x,
998.31, 998.32, 998.30, 998.83, 998.6
IOC, intra-operative cholangiogram; ERC, endoscopic retrograde chol-
angiogram; ERCP, endoscopic retrograde cholangiopancreatography;
MRI, magnetic resonance imaging; MRCP, magnetic resonance cho-
langiopancreatography; GI, gastrointestinal; DVT/PE, deep venous
thrombosis/pulmonary embolism; MI, myocardial infarction.
aPrimary or secondary malignant neoplasm or neoplasm of uncertain
behavior. Includes carcinoma in situ. Includes liver, biliary system,
stomach, pancreas, small intestine, large intestine, spleen, retroperito-
neum and abdominal lymph nodes.
bIncludes strictures, non-malignant obstructions, non-congenital cysts.
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